+

WO1995001453A1 - Essai de mobilite des heteroduplex pour l'analyse de la diversite de sequences d'acide nucleique - Google Patents

Essai de mobilite des heteroduplex pour l'analyse de la diversite de sequences d'acide nucleique Download PDF

Info

Publication number
WO1995001453A1
WO1995001453A1 PCT/US1994/007416 US9407416W WO9501453A1 WO 1995001453 A1 WO1995001453 A1 WO 1995001453A1 US 9407416 W US9407416 W US 9407416W WO 9501453 A1 WO9501453 A1 WO 9501453A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
dna
sequence
fragments
strand
Prior art date
Application number
PCT/US1994/007416
Other languages
English (en)
Inventor
James Ivan Mullins
Eric Lawrence Delwart
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO1995001453A1 publication Critical patent/WO1995001453A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • the present invention describes a method for genetic analysis of gene families: the Heteroduplex Mobility Assay (HMA) .
  • the method has utility in the analysis of gene pools, in particular, gene pools of disease causing microorganisms.
  • the present invention describes a method for evaluating the effects of a disease treatment protocol on DNA sequence variation of a nucleic acid target sequence associated with the disease, using the Heteroduplex Mobility Assay (HMA) or Heteroduplex Tracking Assay (HTA) .
  • the method has utility in evaluating sequence variation among gene pools of disease causing microorganisms and variant disease-related genes, such as oncogenes.
  • Restriction fragment polymorphisms arise when a base change results in the loss or acquisition of a restriction endonuclease cleavage site in a defined DNA sample, for example, a selected region of a viral genome.
  • RFLP analysis is labor intensive and tends not to provide a high level of sensitivity since most changes in a DNA sequence go undetected.
  • ribonuclease is used to cleave any mismatched duplexes. Any cleaved products are then identified by polyacrylamide gel electrophoresis and autoradiography (Myers, et al . , 1985b).
  • Polymerase chain reaction has provided the means to obtain large scale amplification of target DNA (Mullis; Mullis, et al . ) from, for example, defined genomic regions of DNA.
  • a number of approaches have been utilized, for the detection of DNA mutations, in combination with polymerase chain reaction amplified products. These approaches include denaturing polyacrylamide gel electrophoresis (see above and Sheffield, et al . , 1989), single-chain conformation polymorphism analysis (Orita, et al . ) , chemical cleavage of mismatches (Cotton, et al . ) . Constant denaturant gel electrophoresis has also been employed as a screening method for mutations in a defined DNA sequence (Borresen, et al . , 1991) Summary of the Invention
  • the present invention provides a method of evaluating sequence diversity in a mixture of nucleic acids containing a target sequence.
  • amplification primers are selected which are complementary to nucleic acid sequences flanking the target region.
  • the nucleic acids and the primers are combined under conditions that promote the hybridization of the primers to the nucleic acids, thus generating primer/nucleic acid complexes.
  • These complexes are converted to double-strand fragments in the presence of a suitable polymerase and all four deoxyribonucleotides.
  • the primer-containing fragments are amplified by repeated rounds of primer extension until a desired degree of amplification has been achieved.
  • the resulting double-stranded amplified fragments are denatured and renatured to form a population of amplified fragment DNA duplexes. These duplexes are separated on polyacrylamide gels. The relative migration of the duplexes is analyzed to establish the relative degree of sequence relatedness in the population of amplified fragments.
  • the starting nucleic acids can be RNA molecules which are converted to DNA templates using reverse transcriptase.
  • the denaturing step of the method is thermal denaturing, and double-stranded fragments are generated using a thermostable DNA polymerase.
  • the amplified duplexes are separated by polyacrylamide gel electrophoresis (PAGE) , and analyzed by visualization of the amplification products with ethidium bromide staining or autoradiography.
  • the amplified duplexes are separated by PAGE. The locations of the duplexes are then analyzed by transferring the nucleic acids from the gel to a support membrane, and hybridizing the nucleic acid transferred to the membrane with a labelled probe specific for the desired amplification products.
  • the primers may contain at least one detection moiety.
  • the detection moiety can be, but is not limited to, one or more of the following: a radioactive moiety, biotin, digoxigenin, or a chemiluminescent moiety.
  • the method of the present invention can be applied to the analysis of nucleic acid from any infectious agent, including viruses, bacteria, mycoplasma, parasites, and fungi.
  • One exemplary application of the present method is in evaluating intra- and inter-patient sequence diversity of Human Immunodeficiency Virus (HIV) .
  • the present method can be applied to the analysis of sequence variation between defined genetic loci, such as, oncogenes, protooncogenes, and disease- associated loci (e . g . , Duchenne's muscular dystrophy) .
  • This method is also useful to evaluate sequence diversity over time in mixtures of nucleic acids containing a target sequence, where the mixtures are serially obtained from a single source, for example, the single source may be a patient infected with HIV-1.
  • the present invention also includes a method of evaluating sequence diversity between two different sample mixtures of nucleic acids, where the nucleic acids contain a target sequence.
  • the two samples are treated as described above. After amplification, the two amplified samples are mixed, denatured, and renatured. The resulting duplex molecules are separated on polyacrylamide gels. The relative migration of the duplexes is then analyzed to establish the relative degree of sequence relatedness among the amplified fragments of the population.
  • This method can be applied to the analysis of samples from different geographic locations, different patients, or for the same patient with different samples collected over time.
  • the amplified fragments of one sample nucleic acid are labelled with a detection moiety and the labeled fragments are mixed with a molar excess of the amplified fragments of the other sample.
  • Yet another embodiment of the present invention is a method for detecting the presence of a selected nucleic acid target region in a nucleic acid sample.
  • a duplex DNA probe having two complementary strands is selected, where the duplex is homologous to the target region and each strand contains a detection moiety.
  • Amplification primers complementary to nucleic acid sequences flanking the target region of the nucleic acid are also selected.
  • the target region is amplified.
  • the amplified products are denatured and mixed, in molar excess, with the duplex probe.
  • the mixture is denatured, renatured, and analyzed as described above to establish the relative degree of sequence relatedness between the probe and sample target regions.
  • the mixing ratio for amplified fragments to probe is 100:1, amplified fragments to probe.
  • the method of the present invention has been described with reference to using amplification to obtain samples suitable for heteroduplex mobility •analysis.
  • other methods of obtaining nucleic acid samples can be used as well, including, but not limited to, cloning sequences of interest or isolating particular restriction endonuclease digestion products from genomic DNA preparations.
  • the present invention provides a method of evaluating, in mixtures of nucleic acids, the effect over time of a disease treatment, on DNA sequence variation of a nucleic acid target sequence associated with the disease.
  • amplification primers are chosen that are complementary to nucleic acid sequences flanking the target sequence.
  • Mixtures of nucleic acids are serially obtained from a single source. For example, sera is collected from an HIV-infected individual before treatment and at selected time points over the course of treatment.
  • the nucleic acids from each sample and the primers are combined under conditions that promote the hybridization of the primers to the nucleic acids, thus generating primer/nucleic acid complexes.
  • these complexes are converted to double-strand fragments in the presence of a suitable polymerase and all four deoxyribonucleotides.
  • the primer-containing fragments are amplified by repeated rounds of primer extension until a desired degree of amplification has been achieved.
  • the resulting double-stranded amplified fragments are denatured and renatured to form a population of amplified fragment DNA duplexes for each sample.
  • These migration of the duplexes on the gel is analyzed for each sample to determine the relative migration of the duplexes and establish the relative degree of sequence relatedness in the population of amplified fragments.
  • the effect of the treatment is evaluated by comparing the relative degree of sequence relatedness of amplified fragments in each serial sample between the serial samples. Particularly, comparing to the pre-treatment, or zero time point.
  • the starting nucleic acids can be RNA molecules which are converted to DNA templates using reverse transcriptase.
  • the denaturing step of the method is thermal denaturing, and double-stranded fragments are generated using a thermostable DNA polymerase.
  • the amplified duplexes are separated by polyacrylamide gel electrophoresis (PAGE) , and analyzed by visualization of the amplification products with ethidium bromide staining or autoradiography.
  • PAGE polyacrylamide gel electrophoresis
  • the amplified duplexes are separated by PAGE.
  • the locations of the duplexes are then analyzed by transferring the nucleic acids from the gel to a support membrane, and hybridizing the nucleic acid transferred to the membrane with a labelled probe specific for the desired amplification products.
  • the primers may contain at least one detection moiety.
  • the detection moiety can be, but is not limited to, one or more of the following: a radioactive moiety, biotin, digoxigenin, or a chemiluminescent moiety.
  • the method of the present invention can be applied to the analysis of nucleic acid from any microorganism/infectious agent, including viruses, bacteria, mycoplasma, mycobacteria, parasites, and fungi.
  • One exemplary application of the present method is in evaluating intra- patient sequence diversity of Human Immunodeficiency Virus (HIV) .
  • HIV Human Immunodeficiency Virus
  • the present method can be applied to the analysis of sequence variation between defined genetic loci, such as, oncogenes, protooncogenes, and disease-associated loci (e . g . , Duchenne's muscular dystrophy) .
  • defined genetic loci such as, oncogenes, protooncogenes, and disease-associated loci (e . g . , Duchenne's muscular dystrophy) .
  • Yet another embodiment of the present invention is a method for evaluating the effect of a disease treatment procedure on the presence of a selected nucleic acid target region in a nucleic acid sample.
  • a duplex DNA probe having two complementary strands is selected, where the duplex is homologous to the target region and each strand contains a detection moiety.
  • Serial samples are obtained from a single source, e . g . , a first sample before treatment and a second sample after treatment.
  • Amplification primers complementary to nucleic acid sequences flanking the target region of the nucleic acid are also selected.
  • the target region is amplified in each sample.
  • the amplified products from each sample are denatured and mixed, in molar excess, with the duplex probe. Each mixture is denatured, renatured, and analyzed as described above to establish the relative degree of sequence relatedness between the probe and sample target regions.
  • the mixing ratio for amplified fragments to probe is 100:1, amplified fragments to probe.
  • the method of the present invention has been described with reference to using amplification to obtain samples suitable for heteroduplex mobility analysis.
  • other methods of obtaining nucleic acid samples can be used as well, including, but not limited to, cloning sequences of interest or isolating particular restriction endonuclease digestion products from genomic DNA preparations.
  • Figure IB shows the result of heteroduplex mobility (HIV-1 envelope gene DNA) analyzed on a 2.5% agarose gel.
  • Figure IA shows the same . heteroduplex reactions separated on a 5% polyacrylamide gel. The heteroduplex samples were obtained from nested PCR amplifications performed using uncultured HIV-1 seropositive PBMC DNA.
  • Figures 2A to 2E show the results of heteroduplex analysis carried out with gap- and base-pair-mismatch-containing heteroduplex molecules. The heteroduplexes were resolved on agarose (2A) and polyacrylamide (2B-2E) gels.
  • Figure 3A shows a plot of the mobility shifts of heteroduplexes against the % divergence, based on nucleotide sequence analysis, between the two strands of the heteroduplexes.
  • Figure 3B shows some of the heteroduplex mobility assay data used to generate the plot presented in Figure 3A.
  • FIG. 4 shows the results of a heteroduplex mobility assay analysis of variant sequences from different HIV-1 quasispecies.
  • MA is HIV-positive asymptomatic
  • PE and BU were HIV- positive and symptomatic.
  • Figure 5 shows polyacrylamide heteroduplex mobility of inter-individual DNA heteroduplexes using complex DNA mixtures (quasispecies) as probe and target.
  • "*" is unreannealed single stranded DNA.
  • US quasispecies (1, 2, and 3) are from epidemiologically unrelated Americans and quasispecies 4 is from a patient from Moscow.
  • Figure 6 shows polyacrylamide heteroduplex mobility of intra-individual DNA heteroduplexes using complex DNA mixtures (quasispecies) as probe and target.
  • Ml and M27 represent probes derived from the month 1 and 27 quasispecies.
  • Figures 7A, 7B and 7C show polyacrylamide heteroduplex mobility of intra-individual DNA heteroduplexes using subclones derived from uncultured PBMC as probes and quasispecies as target.
  • Figure 8 shows a plot of the mobility shifts of heteroduplexes against the relative genetic distance between the two strands of the heteroduplexes.
  • Figures 9A and 9B show the results of HMA- based and DNA sequence-based estimates of genetic relatedness for variants of the HlV-env gene.
  • homoduplex molecules are typically composed of two complementary DNA strands, where the strands have at least about 98% sequence homology.
  • Heteroduplex molecules are typically composed of two complementary DNA strands, where the strands have less than at least about 98% sequence homology.
  • the functional definition of homoduplex and heteroduplex molecules, in the context of the present invention, is apparent from the results presented below. Typically, in a mixed population of homoduplex and heteroduplex molecules, homoduplex molecules form a single band at a defined position in a polyacrylamide gel and heteroduplex molecules appear as slower migrating bands relative to the homoduplex.
  • Gaps occur when in duplexes consisting of two complementary DNA strands, where the first strand of the DNA contains more nucleotides at an internal site than the second strand DNA molecule, and where these extra nucleotides are flanked by paired-complementary sequences. Gaps can occur in heteroduplexes.
  • Base-pair mismatches typically refers to a single base-pair mismatch flanked by matched base- pairs. Base-pair mismatches also include a series of mismatched base-pairs flanked by matched base- pairs. Base-pair mismatches can occur in heteroduplexes.
  • Quasispecies refers to the totality of members of a species whose genomes have sequence divergence, but where the members still fall within the same species: for example, outgrowth of "a number of sequence variants" (the quasispecies) of HIV-1 from one major infecting variant.
  • "Microorganism” in the context of the present invention includes, but is not limited to, the following groups: bacteria, viruses, fungi, parasites and mycoplasma.
  • Oncogene includes genes that induce cancer or other uncontrolled proliferations of cells.
  • Oncogenes can be mutated or activated (i) proto- oncogenes, or (ii) tumor suppressor genes (both of cellular origin) , associated with the development and/or proliferation of tumor cells. Oncogenes, or portions thereof, may also be of viral origin. I. Observations on Heteroduplex Mobility in Non- Denaturing Polyacrylamide Gels.
  • Amplification reactions (Mullis; Mullis, et al . ) were performed on peripheral blood mononuclear cell (PBMC) DNA taken from an HIV seropositive asymptomatic man. The reactions were carried out using two sequential 25-35 primer extension cycles, where each cycle used a different set of primers (Example 1) .
  • the amplification products were a 1.8 kb (first round) fragment and then a 0.65 kb (second round) internal fragment which corresponded to an internal portion of the HIV-1 envelope gene.
  • Figure IB the expected size band was observed
  • Figure IA shows that the amplified DNA was analyzed on a 5% polyacrylamide gel.
  • the slower migrating bands may have been composed of heteroduplexes formed between divergent molecules during the last melt and reanneal (heat/cool) cycle.
  • procedures expected to reduce or eliminate the formation, of heteroduplexes were performed.
  • the heteroduplexes generated by PCR reactions were subjected to an additional single round of amplification (Example 2, Figure 1, lane 7) . This procedure resulted in the loss of the slower migrating DNA bands. These amplification products were remelted and reannealed under conditions that prevented DNA synthesis. In this reaction mixture, the series of slower migrating bands reappeared (Example 2, Figure 1, lane 8).
  • heteroduplexes containing single 3 bp internal gaps displayed mobility shifts ( Figure 2E) .
  • the effect of gapped sequences on heteroduplex mobility was further examined.
  • a number of HIV-1 fragments from different source materials were amplified and fragments having divergent sequences were identified (Example 2, Figure 2E) .
  • Three HIV-1 fragments having internal deletions (i.e., deletions in HIV-1 sequences) of 3 and 9 base pairs were identified (3 and 9, Figure 2E) .
  • Heteroduplexes were formed between the normal fragments, i.e., those not containing a deletion ("insertion fragments", Figure 2E) , and the deletion fragments.
  • the size of the gap present in the heteroduplex is shown across the top of the figure.
  • HMA could detect a 3 bp deletion in a 3.5 Kb DNA fragment it could also potentially be used to localize and utilize polymorphic sites for linkage mapping.
  • Related micro-organisms could also be rapidly classified into sequence homology subgroups using HMA. HIV-1 tissue culture and PCR contamination (problems of frequent occurrence) can be rapidly checked to ensure the identity and purity of the strain under study.
  • the method of the present invention was employed to develop simple and rapid assays of the relationships between members of DNA sequence families.
  • heteroduplex mobility assays HMA are applied to the study of HIV-1 envelope gene variability, but the method is also applicable to study of other viruses, microorganisms and gene families.
  • DNA fragments (approximately 700 base pairs) encompassing the V3-V5 region of the HIV-1 env gene from a set of 39 molecules of known sequence were amplified (Example 4) .
  • 39 molecules were as follows: thirty one molecules were obtained directly from the PBMC DNA of three North American subjects; six molecules from other independent HIV-1 isolates from North America; and two HIV-1 isolates from Zaire.
  • Heteroduplexes were formed by pairwise combination of sequences from the same individual subject and between epidemiologically unrelated North American and Zairian isolates. The relative mobility of the heteroduplexes compared to the known genetic divergence (Figure 3A) .
  • Mobility shifts observed with some sequences derived from a long term infected asymptomatic individual (MA) were atypically large and partially overlapped those observed between independent US isolates ( Figure 3A) . Further, the mobility shifts were generally lower in the HIV-1 pools from subjects with AIDS than from subject MA. When unpaired nucleotides were counted as mismatches the average genetic divergence increased more for the MA groups than for the AIDS patients. The relatively higher number of gaps distinguishing MA sequences is therefore likely to account for the greater mobility shifts observed. HIV-1 env DNA derived from two MA PBMC samples collected 22 months apart were paired to each other for heteroduplex analysis.
  • Heteroduplex mobilities were plotted against genetic distance, as determined by percent sequence divergence (Figure 3A) .
  • Heteroduplexes differing by only mismatches displayed a better correlation between mobility and divergence but with a lower slope ( Figure 3A, circles) .
  • the scatter of values in the intra-subject range may be due to a large influence of gaps on electrophoretic mobility.
  • a standard curve for heteroduplex mobility can be generated using pair-wise combinations of DNA molecules having known genetic distances, based on sequence comparisons between the molecules. For example, a region of a virus, such as the HIV env gene, can be selected. A number of variants are sequenced. Heteroduplexes are formed in pair-wise combinations between the variants. The genetic distance (i.e., percent sequence divergence based on mismatch) is then plotted against the heteroduplex mobility for each pair- wise combination. A sample of one such plotted is presented as Figure 8.
  • Heteroduplexes are then formed between pair- wise combinations of DNA samples, of the same region, by the method of the present invention.
  • Heteroduplex mobilities are determined using HMA and the mobilities compared to the standard curve to establish the degree of relatedness between each pair-wise combination. This information can be used to generate phylogenetic trees such as is shown in Figure 9A.
  • Figure 9A shows a phylogenetic tree based on HMA. Heteroduplex mobility data was recalculated into genetic distances using a HMA-DNA distance curve ( Figure 8) . The tree was generated using the "FITCH” program (Phylip 3.4 shareware/freeware) (Felsenstein, 1989) .
  • Figure 9B shows a phylogenetic tree based on env gene DNA sequences. Subtypes, identified by Myers (Myers, et al . , 1992) are adjacent to boxes. Isolates present in Figure 9A that are not included in Figure 9B are indicated by an asterisk in Figure 9A.
  • heteroduplex mobility assay described herein provides a means for the rapid estimation of the degree of relatedness between members of gene families. HMA requires only a neutral polyacrylamide gel and yields results in hours. The method allows the determination of sequence relatedness without resorting to sequencing analysis (for example, Figure 9A) . Under the conditions described above, nucleotide gaps and mismatches can be observed in heteroduplexes using the method of the present invention. The preferred size range for these heteroduplexes is approximately 100 to 1500 base pairs in length, although larger-sized heteroduplexes can be used as well.
  • heteroduplexes containing an internal gap display mobility shifts which generally increased with the size of the gap.
  • 3 base gaps could be detected in heteroduplexes at least 3 kb in length.
  • the method of the present invention provides the means to determine approximate levels of DNA sequence diversity in a population of nucleic acid sequences both within and between individuals.
  • the following examples using Human Immunodeficiency Virus sequence variations are illustrative of the method of the present invention.
  • sequences of interest can be cloned (e . g . , in a lambda vector; Sambrook, et al . ) from two different sources.
  • the sequences of interest are independently isolated away from vector sequences (e.g., by restriction endonuclease digestion and fragment purification) .
  • These two samples can then be combined, denatured, renatured, and the resulting heteroduplexes analyzed as discussed below.
  • the method of the present invention was employed to compare the diversity of HIV-1 env genes found in PBMC versus those found after co- culture. After co-culture, in 8/12 cases a single genomic variant, a descendant of an originally present variant, was observed. In 2/12 cases two genomic gap-phenotype variants were observed and in 2/12 cases three genomic gap-phenotype variants were observed. In each of the 12 independent cultures a marked reduction of diversity was observed. When similar analysis was extended to 12 other co-cultures propagated from 2 to 8 weeks and a further 8 un-cultured in vivo quasispecies from different patients the pattern of low sequence complexity following co-culture and higher sequence complexity in vivo was maintained.
  • lane "Cult.” presents HMA data for DNA samples amplified from a four week co-culture of HIV-infected PBMC. These results show a reduced sequence divergence in HIV- DNA obtained from co-cultured cells relative to the DNA derived from PMBC over time. Further, the comparison between two AIDS patients and an asymptomatic subject (Example 5) demonstrates that the overall level of HIV-1 env gene diversity in
  • PBMC DNA (not co-cultured) samples was observed to be lower in subjects with low CD4 cell levels (PE and BU, Figure 4) than in those with higher CD4 cell levels (MA time-points, Figure 4) .
  • the above results demonstrate that in vitro PBMC co-culture consistently results in the outgrowth of 1-3 distinguishable variants, confirming two previous studies based on extensive DNA sequence analysis (Meyerhans, et al . , 1989; Kusumi, et al . , 1992). It is possible that the diverse viral genes observed in HIV-1 infected PBMC represent a record of prior infection in cells that survived an abortive infection with noninfectious virus.
  • the culture milieu may impose selection pressure resulting in preferential replication of viral variants that are able to propagate quickly under the culture conditions.
  • the heteroduplex mobility assay of the present invention may be used to distinguish between these possibilities: HMA can be used to effectively monitor the growth kinetics of specific variants in vitro .
  • the data presented above also demonstrate that env gene complexity within the blood of five subjects with AIDS or low CD4 cell numbers was lower than in six asymptomatic seropositive subjects. Outgrowth of a limited number of fast replicating variants in the presence of a declining immune system has been previously implicated in this apparent lower quasispecies complexity (Kuiken, et al . , 1992; Tersmette, et al . , 1989) .
  • the method of the present invention can be applied to the analysis of any number of microorganisms including bacteria, parasites, and other infectious agents.
  • Exemplary microorganisms include, but are not limited to, the following:
  • probes for any target nucleic acid can be selected from a region of the microorganism's genomic material, such as rRNA (for example, as in Weisburg, et al . ) . In this way probes can be identified that will form homoduplexes to identify specific species. Formation of heteroduplexes indicates that the sequences that have diverged from the probe sequence.
  • the method of the present invention can also be applied to the analysis of any nucleic acid containing entity, including subcellular organelles such as chloroplasts and mitochondria. Further, the method of the present invention can also be used in screening methods for the evaluation of therapeutic treatments of any of the above microorganisms.
  • the methods disclosed herein are useful for evaluating, in mixtures of nucleic acids (such as, nucleic acids obtained from tissue samples) , the effect over time of a disease treatment, on DNA sequence variation of a nucleic acid target sequence associated with the disease.
  • Therapeutic treatments typically are directed to the resolution, elimination, or relief of a disease state, as, for example, caused by a microorganism/infectious agent.
  • the heteroduplex mobility assay can be used to establish a base-line of infection in any selected patient before the onset of treatment. Diversity of the HIV virus can be determined as described below for different cell and tissue samples from the patient. Typically, blood and plasma samples are then serially collected from the subject throughout the therapeutic trial. Changes during treatment in overall diversity of the HIV population can be monitored by the heteroduplex mobility assay. The turnover of specific variants can be monitored during the course of treatment use labeled tracer DNA (e.g., see below, "(b) Quasispecies Replacement within an Individual) . The emergence of new variants can also be detected by using specific HIV probes obtained from samples obtained from different time points in the course of the therapy. Representation of such variants in the population of HIV molecules can also be accomplished user labeled tracer DNA (e . g . , Example 7, Tracking HIV- 1 Sequence Variants) .
  • labeled tracer DNA e.g . , Example 7, Tracking HIV- 1 Sequence Variants
  • the method of the present invention is used to evaluate treatment of HIV with 3'-azidothymidine (AZT) .
  • the present method allows the evaluation of the effect of treatment on (i) quasispecies diversity, and (ii) the representation of particular variants within sample populations, in particular, variants pre- existing in the host that emerge after the onset of AZT therapy. Further, the method allows the determination of the time-frame in which any AZT- resistant mutants arise during the course of treatment. After the identification of such mutants, the methods of the present invention can be used to assess the presence of such mutants in samples obtained before the mutants were observed (using, for example, the tracer method of Example 7) . Further, the present methods can be used to follow the fate of such mutants during the course of further treatment, by, for example, dideoxyinosine (DDI) .
  • DAI dideoxyinosine
  • Tuberculosis (TB) infections are another example of how the method of the present invention can be used to monitor the effects of a disease treatment.
  • the heteroduplex mobility assay can be used to monitor the presence and diversity of strains of Mycobacterium tuberculosis growing within an individual. For example, a 383 bp segment of the gene encoding the 65 kDa mycobacterial surface antigen can be amplified (Ghossein, et al . , 1992) from samples obtained from a patient under treatment and analyzed by HMA and/or HTA.
  • the assay can also be used to detect the specific loss or increase in abundance of TB variants during therapy.
  • HTA Heteroduplex Tracking Assay
  • the labeled probe is derived from standard TB strains or variants identified in the patient during the course of treatment.
  • Such probes are used to track the representation of different Mycobacterium tuberculosis populations over time: before, during and following therapy.
  • the present methods can be used to help identify differential strain specificity to anti- tuberculosis drugs.
  • the HTA methods of the present invention are used to monitor when variants come and go within the course of any infection and what the impact of any treatment has on the variant populations.
  • Specific loci associated with drug resistance for a particular microorganisms can be used for tracking different populations of a microorganism using the methods of the present invention, where the variant loci are amenable to detection using HTA.
  • the present assay can be used to evaluate diversity in cell culture systems and animal models as well as patients.
  • Phylogenetic relationships can be established by the method of the present invention. Phylogenetic analysis can be carried out with almost any selected genomic sequence, such as, glycolytic enzymes (like phosphoglycerate kinase (Vohra, et al . ) ) or rRNA sequences. Phytogenic relationships between plants can be established, using, for example, sequences derived from plastid ribosomal RNA operons (Wolfe, et al . ) .
  • HIV-1 envelope sequence variants were simultaneously amplified from peripheral blood mononuclear cell (PBMC) DNA by nested polymerase chain reactions (PCR) over the PBMC DNA.
  • PBMC peripheral blood mononuclear cell
  • PCR nested polymerase chain reactions
  • V3 to V5 regions of the env genes The genetic relationship between different DNA quasispecies was determined by radioactively labeling one quasispecies DNA during PCR and reannealing it with an excess of unlabeled DNA from another quasispecies.
  • Other labeling methods, in addition to radioactive labelling, can be employed: for example, labeling with biotin, digoxigenin, or chemiluminescent labels (Tropix, Inc. (Bedford, MA) ) .
  • the method of the present invention also provides a means to monitor the evolution of sequence complexity in cultured cells as well as in vivo .
  • the method of the present invention has been used to track the presence of quasispecies of HIV-1 obtained from PMBC co-cultures.
  • the method of the present invention can be applied to variant tracking for other microorganisms.
  • the method of the present invention is also useful to analyze the in vivo evolution of quasispecies complexity for a given microorganism.
  • PBMC DNA samples from four infected individuals prior to their sero-conversion were analyzed. From two samples, single molecules of HIV-1 DNA were amplified: 5 and 7 positive PCR end point sequences were obtained from these two samples. Pair-wise heteroduplex analysis of these PCR end points, using two different probes, showed no mobility shifts. This result indicates that these pre-seroconversion quasispecies were made up of identical or very similar sequences.
  • Patient 1058 first showed signs of low level envelope sequence complexity three months after the initial antigenemia peak. Further increase in quasispecies complexity was not apparent until 54 months later, simultaneous with a noticeable increase in HIV-1 DNA load and a detectable p24 antigenemia. The result that HIV-1 load (PBMC HIV-1 DNA) fell with sero-conversion and then within months rose to intermediate levels is consistent with previous observations (Daar, et al . ; Clark, et al . ) .
  • Patient 1058 whose quasispecies appeared to remain homogeneous longer, retained sequences highly related to the major pre-seroconversion variant at high levels for the entire observation time of 57 months.
  • a noticeable mobility shift beyond 21 months reflected the accumulation of nucleotide substitutions, which results in small mobility shifts, relative to the major infecting variant and the replacement of the quasispecies with such variants.
  • Sequencing of PCR end points from each patient confirmed that (i) the pre- seroconversion quasispecies were highly related, and (ii) the later sequences had diverged from the pre-seroconversion sequences.
  • the method of the present invention also provides a means to track sequence variation between microorganisms isolated from different geographic locations by taking advantage of the gradual increase in mobility shifts observed with increasing sequence divergence between reannealed DNA strands. Analysis of this kind allows the rapid identification of sequence variants within species with, for example, viruses, such as, HIV and influenza.
  • DNA fragments encoding the V1-V5 of the HIV-1 envelope gene (env) from different geographic origins have been amplified and evaluated by the method of the present invention. Using 20 env fragments, whose DNA sequences were known, a plot was made of the heteroduplex mobility shift versus genetic distance.
  • Thailand sequences fell into two groups. In the first group the 4 independent isolates from Northern Thailand (Cheng-Mai) formed a very close cluster whose sequence diversity was comparable to that found within individuals. The two sequences from Southern Thailand (Bangkok) , while very divergent from those in Cheng-Mai, were themselves more related.
  • heteroduplexes consisting of DNA strands from different sources, such as, different geographic, hospital or patient origins, can be analyzed by the method of the present invention.
  • the first round primers were ED3 and ED14
  • the second round primers were ED5 and ED12 (Example 1) .
  • the Zambia/Zimbabwe cluster were most related to the Bombay, India cluster. US/European sequences formed a large single related group with related sequences in Bangkok, Thailand and Brazil. A single HIV-1 cluster in the US and Europe could reflect the descendence of most US/European isolates from one or a few highly related sequences in a manner similar to what is now seen in N. Thailand and Bombay.
  • microorganism e . g . , HIV
  • sequence variation can be rapidly determined by the method of the present invention. If successful vaccination is dependent upon or improved by a close match with the challenge strain the manufacture of vaccines related to local infectious microorganisms could increase vaccine efficacy. Vaccinated individuals, who nonetheless became infected, could be rapidly analyzed to determine the infecting microorganism subgroup. Such analysis should allow a more rapid appreciation of the effect of sequence variability on vaccine efficacy.
  • the method of the present invention is useful for tracking quasispecies and sequence variations in samples containing viral nucleic acids.
  • the method of the present invention can also be applied to tracking other pathogen-derived nucleic acids, for example, nucleic acids from bacteria, mycoplasma, protozoans, and parasites.
  • the results presented above demonstrate the usefulness of the method of the present invention for phylogenetic analysis and grouping of isolated microorganisms.
  • This screening method can be applied to a number of microorganisms, as discussed above.
  • the present method is useful in monitoring changing populations of gene sequences during the course of infection and disease. Further, the method is useful for tracking individual genomic variants and assessing overall levels of diversity, and for transmission of microorganism variants between individuals (e . g . , in the case of HIV-1, maternal- fetal' transmission) and within populations (e . g. , in the case of HIV-1, in proposed WHO vaccine trial sites) .
  • Another embodiment of the present invention is the use of specific probes to identify variants based on the formation of homoduplex complexes. For example, sequences corresponding to a particular HIV variant can be cloned and amplified. These cloned sequences are then used as a probe against HIV molecules isolated from a number of test sources. Using the method of the present invention, if homoduplexes are formed in hybridization reactions between the probe and the test source HIV, then the test source HIV is shown to be similar to the cloned probe variant. If on the other hand heteroduplexes are formed between the probe and test sequences, then sequence divergence between the probe and test sequences is indicated.
  • a battery of probe sequences can be established for major variants and then used in routine screening of test samples to identify the particular variant present in the test sample.
  • probe sequences can be selected from the mycoplasma 16S rRNA for a number of species. Probe sequences for each species are generated by polymerase chain reaction using primer sequences conserved between mycoplasma species, but which flank regions of sequence divergence. DNA sequences corresponding to mycoplasma 16S rRNA sequences are available in the "GENBANK" data base for many mycoplasma species.
  • a nucleic acid sample derived from a test source, such as mycoplasma infected tissue culture is then amplified with the same primers.
  • the resulting amplified test DNA is separately mixed with tracer amounts of labeled probe DNA (Example 6) , denatured, renatured and resolved on polyacrylamide gels. Presence of homoduplexes indicates which species of mycoplasma is present in the infected source.
  • This method is a self-confirming assay, in that, homoduplex formation should occur with only one probe sequence (representing one species) and heteroduplex formation with the other probes.
  • Gapped probe molecules can be generated to regions of known sequence variation in a target gene.
  • the mobility of heteroduplexes, formed between a target strand and a second strand containing an internal deletion relative to the target strand is affected by the sequence of looped out and the neighboring DNA sequences (Example 3, Figure 2E) . Accordingly, the mobility of such heteroduplexes can be used to evaluate the sequence present in the target molecule that bridges the gap.
  • the use of gapped probe molecules provides a way to identify the presence of mutations in a sample target strand relative to standard target strand that contains a wild-type sequence. This method is particularly useful in the analysis of genes where the location of important mutations has been pre-determined.
  • the heteroduplex tracking assay (HTA) of the present invention can be used to evaluate the extent of infiltration of tumor cells within a tissue population.
  • exemplary potential target sequences are protooncogenes, for example, including but not limited to the following: c- myc, c-myb, c-fos, c-kit, ras, and BCR/ABL (e . g. , Gazdar, et al . , 1990; Wickstrom; Zalewski, et al .
  • oncogenes/tumor suppressor genes e . g . , p53, Bayever, et al .
  • deletions, insertions, rearrangements and divergent sequences in such genes or in the regions of DNA surrounding the coding sequences of such genes all allow formation of heteroduplexes between amplified variant DNA and amplified DNA from normal cells.
  • Specific probes can be designed to the variant oncogenic gene and the labeled probe can be used in HTA.
  • the advantageous sensitivity of HTA is used to detect tumor cells within a population by heteroduplex tracking with sensitivities routinely as low as 1 in 100 cells.
  • therapies that affect his prevalence can be ascertained through the use of HTA.
  • E. coli DNA polymerase I (Klenow fragment) was obtained from Boehringer Mannheim Biochemicals (Indianapolis, IN) .
  • T4 DNA ligase and T4 DNA polymerase were obtained from New England Biolabs (Beverly, MA) ; Nitrocellulose filters were obtained from Schleicher and Schuell (Keene, NH) . Restriction enzymes were purchased from commercial vendors and used as per the manufacturer's instructions.
  • Synthetic oligonucleotide linkers and primers were prepared using commercially available automated oligonucleotide synthesizers.
  • custom designed synthetic oligo- nucleotides may be purchased, for example, from Synthetic Genetics (San Diego, CA) .
  • DNA labeling kits can be obtained from Boehringer-Mannheim Biochemicals (BMB, Indianapolis, IN) and Bethesda Research Laboratories (Gaithersburg, MD) .
  • Polymerase chain reaction reagents and equipment are available from Perkin Elmer Corporation (Norwalk, CT) . Routine molecular biology manipulations were carried out by standard procedures as taught, for example, by Ausubel, et al . , Maniatis, et al . , or Sambrook, et al .
  • PBMC Peripheral blood mononuclear cells isolated by "FICOLL/HYPAQUE" density gradient centrifugation were washed twice with phosphate buffered saline (PBS; Gibco-BRL, Gaithersburg MD) .
  • PBS phosphate buffered saline
  • Mullis, et al . were carried out in two rounds using nested primers. Typically, 2 ul of the first round reaction product was added to a second round of PCR with internally annealing primers.
  • First round primers were typically selected from one of the following groups: ED3 (SEQ ID NO:l), corresponding to positions 5956-5985 on the HIV-1- HXB2 genome (Ratner, et al . ) and ED12 (SEQ ID NO:2), corresponding to the complement of positions 7810-7781 on the HIV-1-HXB2 genome; or ED3 and ED14 (SEQ ID NO:7) , corresponding to positions 7936-7966 on the HIV-1-HXB2 genome.
  • ED3 SEQ ID NO:l
  • ED12 SEQ ID NO:2
  • ED3 and ED14 SEQ ID NO:7
  • One set of second round primers was ES7 (SEQ ID NO:3), corresponding to the M13 universal primer followed by positions 7000-7020 of HIV-1- HXB2) and ES8 (SEQ ID NO:4) , corresponding to the complement of the M13 reverse sequencing primer followed by positions 7667-7647 of HIV-1-HXB2) .
  • the second round primers give rise to an amplification product of 704 bp of which approximately 627 bp are template dependent: the actual size of the amplification products depends on the size of deletions and insertions within the target molecule relative to the HIV-1-HXB2 template.
  • a second set of second round amplification primers contain the sequences ED5 (SEQ ID NO:8), positions 6562-6588 of HIV-1-HXB2, and ED12 (SEQ ID NO:2), complement of positions 7792-7822 of HIV-1-HXB2.
  • first round primers contained ED3 and ED14
  • second round primers contained ED5 and ED12.
  • a third set of second round amplification primers were ES5 (SEQ ID NO:5), positions 7521- 7540 of HIV-1-HXB2, and ED4 (SEQ ID NO:6), complement of positions 7741-7712 of HIV-1-HXB2. Use of primers ES5 and ED4 yielded an -220 bp amplification fragment.
  • Each PCR reaction employed variable amounts of template DNA (up to 1 ⁇ g) , 1.8 mM MgCl2, 20 pmole of each primer in 50 mM KCl, 10 mM Tris-HCl pH8.3, 200 uM of each dNTP, 2.5 units of Taq DNA polymerase (Perkin Elmer-Cetus, Emeryville, CA) , and 10% glycerol in a final volume of 50ul.
  • PCR reactions were carried out, essentially as per the manufacturer's suggestion, in a Perkin Elmer Thermocycler Model 124 for 25-35 cycles using 1 sec ramp times between steps of 94°C for 1 minute, 57°C for 45 sec, and 72°C for 1 minute.
  • heteroduplex resolution a 5 minute 72°C extension step was linked to the last cycle. Heteroduplex resolution was carried out by transferring 10 ⁇ l of the second round PCR reaction to 90 ⁇ l of fresh standard PCR reaction mix (with 100 pmole of each primer) followed by one denaturation and 5 minute extension cycle at 72°C.
  • HIV-1 DNA Titration of HIV-1 DNA in PBMC DNA was performed essentially as described by Simmonds, et al . , (1990) . Briefly, HIV-1 DNA was titrated using duplicate serial 5 fold dilutions of input infected PBMC DNA and maintaining a constant 1 ug of human genomic DNA.
  • Single molecule HIV DNA templates from subject PBMC were also derived by endpoint dilution and used to generate probe sequences for tracking their representation in PBMC DNA over time. Endpoint reactions were subjected to the heteroduplex mobility assay of the present invention to verify template homogeneity.
  • PCR and cloning artifacts were minimized by sequencing HIV-1 variants directly from PCR fragments derived by nested PCR from single molecules of HIV-1 (Simmonds, et al . , (1990)). This procedure also provides variant frequencies representative of the prevalence of the HIV-1 molecules within the quasispecies; as may not happen following subcloning, when a single provirus can give rise to two or more subclones.
  • DNA sequencing of isolated amplification products or clones of HIV DNA was carried out by standard dideoxy sequencing reactions (U.S. Biochemical, Cleveland OH) .
  • Heteroduplexes were then separated on 5% polyacrylamide gels (30:0.8 acrylamide:Bis) at 250V for 3 hours in IX TBE (0.088M Tris-borate, 0.089M boric acid, 0.002M EDTA) or 2.5% agarose gels at 100V for 1.5 hrs. in TAE buffer (0.04M Tris-acetate, 0.001M EDTA) .
  • the gels were stained with ethidium bromide and photographed. The temperature at which the gels are maintained during electrophoresis can affect the mobility of the heteroduplexes.
  • Nested PCR using two sequential 25-35 primer extension cycles was used to amplify a 1.8 kb and then a 0.65 kb internal fragment of the HIV-1 envelope gene directly from peripheral blood mononuclear cell (PBMC) DNA taken from an HIV seropositive asymptomatic man (Example 1) .
  • PBMC peripheral blood mononuclear cell
  • nested PCR was carried out using only one round of 25 primer extension cycles to amplify a 0.65 kb internal fragment of the HIV-1 envelope gene directly from the PBMC DNA-described above. In these reactions, the products demonstrate that the level of slower migrating
  • Heteroduplexes were formed by melting and reannealing mixtures of DNA fragments essentially as described above.
  • Samples of HIV-1 were obtained from a variety of sources. Briefly, molecular clones of HIV-1 genes in plas ids were obtained (e . g . , Kusumi, et al . ) . Sequences were either obtained from published sequences or by employing standard sequencing techniques with using isolated HIV sequences.
  • Heteroduplexes were formed as described in Example 1. The migration of the heteroduplexes and homoduplexes were compared in polyacrylamide and agarose gels as described in Examples IC and 2.
  • Figures 2B and 2C show photographs of ethidium bromide stained 5% polyacrylamide gels containing, in each lane, heteroduplexes formed from a mixture of two PCR products, each PCR amplified product has been sequenced.
  • sequence percent mismatch ranges from 0.16 to 1.11. Also, the presence (+) or absence (-) of gaps in the heteroduplex sequences are indicated.
  • lane 2 contains molecular weight markers derived from a Haelll digest of 0X174.
  • HIV-1 fragments from different source materials were amplified (second round primers ES7 and ES8) and sequenced as described above (Example 1) .
  • the amplification products were normally 704 bp of which approximately 627 bp are template dependent.
  • a number of 704 bp fragments having divergent sequences were identified ("Insertion" fragments, A-H, Figure 2E) .
  • the duplicate lanes correspond to fragments having the same nucleotide sequence that were derived from different sources.
  • three HIV-1 fragments having internal deletions i . e . , deletions in HIV-1 sequences
  • Heteroduplexes were formed between the insertion fragments and the deletion fragments.
  • the heteroduplexes were electrophoretically separated as described in Example 1.
  • the gels were stained with ethidium bromide and photographed. The results are shown in Figure 2E.
  • the bottom band in each lane corresponds to homoduplexes.
  • the lanes marked "M" are molecular weight standards.
  • heteroduplexes formed with deletion fragment 12 have a range of mobilities where the mobilities are dependent on the sequences present in the looped out insertion of the second fragment A, B, C or D.
  • HIV-1 env sequences (V3-V5) from within the same and between different seropositive individuals, were amplified (second round primers ES7 and ES8) and sequenced as described above (Example 1) .
  • the amplification products were normally 704 bp of which approximately 627 bp are template dependent.
  • MA89-91 is a comparison of sequences derived from subject MA 22 months apart in 1989 and 1991
  • US/US is a comparison of sequences from epidemiologically distinct viruses from subjects within the United States of America
  • US/AFR is a comparison of sequences from 6 US [pNL4-3, SF2, SF162, MA5 (Myers, et ai . , 1992); BU01, PE01] and 2 Zairian (Africa) subjects [NDK, MAL (Myers, et al . , 1992)].
  • NDK/MAL comparison which displayed the fastest mobility and least sequence divergence in the group.
  • heteroduplex mobilities on non-denaturing polyacrylamide gels were calculated as the average distance of migration of the two heteroduplex bands divided by the distance of migration of the homoduplex bands.
  • the sequence divergence between the nucleic acid sequences from each HIV-fragment source were determined by comparison of the nucleic acid sequences using the program DOTS (Kusumi, et al . , 1992) .
  • DOTS Koreanumi, et al . , 1992
  • Figure 3B shows representative heteroduplex mobility data using the above DNA sources and a 5% polyacrylamide gel with representative heteroduplexes formed from the intrasubject, intersubject and US/AFR groups, respectively.
  • the heteroduplex mobility assay described above was used to compare the diversity of HIV-1 env genes found in isolated PBMC versus those found after co-culture of the PMBC (Kusumi, et al . , 1992).
  • DNA was isolated from PMBC as described in Example 1. Titration of the HIV-1 DNA in the PBMC DNA was performed as described in Example 1.
  • Each PBMC DNA sample contained at least 20 molecules of HIV-1 DNA, determined by end point PCR. In each sample the HIV-1 molecules were simultaneously PCR amplified as described above using ES7 and ES8 as second round primers in nested PCR reactions.
  • Figure 4 shows the results of heteroduplex mobility analysis of viral quasispecies obtained from PBMC and after virus isolation in co-culture.
  • lane numbers refer to the month of collection of PBMC from an asymptomatic subject (MA) beginning approximately 5 years after infection (Kusumi, et al . , 1992) .
  • Duplicate nested PCR reactions are shown for the 1 and 7 month time points.
  • Cyult refers to DNA samples amplified from a four week co-culture of HIV- infected PBMC (time point, 1 month) with uninfected PBMC.
  • Lane “M” contains molecular weight markers.
  • PE” and "BU” correspond to source PMBC DNA obtained from two AIDS patients.
  • HIV-1 envelope sequence variants were simultaneously amplified
  • Example 1 from peripheral blood mononuclear cell (PBMC) DNA by nested polymerase chain reactions (PCR) over the V3 to V5 regions of the env genes (Example 1, using ES7 and ES8 as second round primers in nested PCR reactions) .
  • PCR nested polymerase chain reactions
  • the genetic relationship between DNA molecules amplified from different source DNAs was determined by radioactively labeling one group of DNA molecules during PCR and reannealing those labeled molecules with an 100-fold excess of unlabeled DNA from another source material.
  • probe "tracer” i.e., labelled amplified DNA molecules
  • the resulting heteroduplexes were then separated by polyacrylamide electrophoresis (Example 1) .
  • the gels were then exposed to X-ray film (with or without intensifying screens) and the resulting autoradiograms analyzed.
  • Figure 5 shows the results of one such "tracer”/"driver” analysis.
  • PMBC DNA was isolated from four sources, three US HIV-positive samples and one African HIV-positive sample (from clouds) .
  • Nested DNA amplification reactions were carried out as described in Example 1 using primers ES7 and ES8.
  • the probes were labeled PCR products from each PMBC sample.
  • the products were radiolabeled by addition of 10 ⁇ Ci of a 32 P-dCTP and 30 ⁇ M of each dNTP to the second round of a nested PCR reaction.
  • Quasispecies change within an asymptomatic HIV-positive man was monitored as follows. HIV-1 envelope DNA was isolated by nested PCR amplification, using ES7 and ES8 as second round primers, from PMBC DNA. The PBMC DNA was isolated from the subject at different time points spanning 27 months. "Tracer"/"driver” analysis was carried out as described in Example 5 using amplified DNA from each PMBC time point. In this example, the source of the PMBC DNA was asymptomatic patient MA, described above in Example 5. Probes were derived from PCR products from the month 1 (Ml, Figure 5, left panel) or month 27 (M27, Figure 5, right panel) . Month 1 and 27 products were radiolabeled by addition of 10 ⁇ Ci of a 32 P-dCTP and 30 ⁇ M of each dNTP to the second round of the nested PCR reaction.
  • the resulting reannealed duplex products were electrophoretically separated on a 5% polyacrylamide gel.
  • An autoradiograph of the gel is shown in Figure 6.
  • the asterisk (*) to the left of the panel denotes the position of single stranded DNA.
  • the labeled probe DNA (tracer) is shown at the top of the figure: Ml corresponds to the quasispecies amplified from the first month PMBC and M27 corresponds to the quasispecies amplified from the 27 month PMBC.
  • the driver DNA is shown in the second line of the figure: the number represents the month the sample was obtained.
  • the progressive disappearance of labeled homoduplexes (Ml-tracer) and the increasing mobility retardation of the labeled heteroduplexes (Ml-tracer) as time increased between the probe and target quasispecies was observed.
  • the M27- tracer demonstrates the replacement of one set of sequences (M27-tracer:Ml-driver) by another (M27- tracer:M27-driver) within two years.
  • PMBC DNA was isolated from an HIV-positive individual over a twenty seven month period. Variant sequences were cloned from the 1 month PMBC sample (clones MA20 and MA16) and from the 22 month sample (clone MA305) : the source DNAs for these clones were the unamplified PMBC DNA samples. HIV sequences (for example, env sequences) were cloned using standard vectors and techniques (Kusumi, et al . , 1992; Ausubel, et al . ; Sambrook, et al . ) . The cloned sequences were labeled with radioactive moieties by end-labeling, random-priming or nick-translation (kits for each method available from Gibco/BRL, Gaithersburg, MD) .
  • the HIV env sequences were amplified as described in Example 1 using primers ES7 and ES8 and the sequentially obtained PBMC DNAs as template (as in Example 6) .
  • the cloned DNAs were used as probes to determine their prevalence in sequential PBMC samples as described in Example 6. The results of this analysis are shown in Figures 7A, 7B, and 7C.
  • Figure 7 the numbers at the top of the lanes correspond to the month that the sequential PMBC sample was isolated.
  • the clone names are indicated at the top of each panel of the figure ( Figure 7A is MA20, Figure 7B is MA16, and Figure 7C is MA305) .
  • Ml indicates that the probe was obtained from the 1 month PMBC DNA sample.
  • M22 indicates that the probe was obtained from the 22 month PMBC DNA sample.
  • "s.s.” is the location of the labeled single-strand DNA and "H" is the location of the homoduplex.
  • One clone (MA20) obtained from the 1 month PMBC DNA detected the presence of its corresponding variant only in the quasispecies (i.e., the family of variant HIV sequences present in the ' PMBC sample) from which it was cloned ("H", lane 1, Figure 7A) .
  • Another clone, MA305, which represents a different quasispecies, was present in the amplified PMBC DNA from which it was obtained ( Figure 7C, lane 22) and also in two subsequent samples ( Figure 7C, lanes 23 and 27) .
  • the third clone, MA16 was found in the amplified PMBC DNA from which it was obtained ( Figure 7B, lane 1) and also in subsequent PBMC samples up to 22 months later ( Figure 7B, lanes 6, 7 and 22) .
  • the lane marked "C” is a control reaction showing the results of mixing the tracer clone DNA with the driver DNA corresponding to the PMBC sample from which the clone was obtained.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Les hétéroduplex formés entre différents membres d'une famille de gènes migrent plus lentement dans les gels de polyacrylamide non dénaturants (PAGE) que les homoduplex. Les hétéroduplex comportant des délétions ou des insertions de l'ordre d'un seul nucléotide à peine sont identifiés par un retard de mobilité dans le PAGE. Les hétéroduplex ne contenant que des non-appariements présentent aussi un décalage de la mobilité dont l'importance dépend du pourcentage de divergence de la séquence. Les décalages de la mobilité des hétéroduplex présentant une délétion ou une insertion sont affectés par la taille, la position et le nombre de délétions ou d'insertions et par la séquence des nucléotides uniques et non appropriés voisins. L'essai de mobilité des hétéroduplex (EMH) et l'essai de recherche des hétéroduplex (HRH) selon l'invention peuvent servir à rechercher l'évolution de quasi-espèces virales chez des sujets et entre des sujets, à rechercher les espèces d'agents infectieux et à contrôler les modifications de la séquence d'ADN, notamment par l'identification et la recherche des polymorphismes cellulaires de l'ADN.
PCT/US1994/007416 1993-07-01 1994-06-30 Essai de mobilite des heteroduplex pour l'analyse de la diversite de sequences d'acide nucleique WO1995001453A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8701093A 1993-07-01 1993-07-01
US08/087,010 1993-07-01
US24137394A 1994-05-11 1994-05-11
US08/241,373 1994-05-11

Publications (1)

Publication Number Publication Date
WO1995001453A1 true WO1995001453A1 (fr) 1995-01-12

Family

ID=26775801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007416 WO1995001453A1 (fr) 1993-07-01 1994-06-30 Essai de mobilite des heteroduplex pour l'analyse de la diversite de sequences d'acide nucleique

Country Status (1)

Country Link
WO (1) WO1995001453A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020070A1 (fr) * 1995-11-29 1997-06-05 The Anthony Nolan Bone Marrow Trust Procedes pour separer et/ou identifier des molecules d'adn
WO2000024935A3 (fr) * 1998-10-26 2000-07-13 Univ Yale Procede fonde sur les differences de frequence d'alleles destine au clonage de phenotypes
ES2190877A1 (es) * 2001-06-26 2003-08-16 Univ Santiago Compostela Metodo gedap (genotyping based on diagnostic amplification products) para detectar y/o prevenir errores de genotipado a partir de los productos de amplificacion de un locus polimorfico.
GB2435326A (en) * 2006-02-15 2007-08-22 Cell Analysis Ltd Heteroduplex analysis of non-human analytes
US7935480B2 (en) 2004-12-23 2011-05-03 Health Protection Agency Detection of nucleic acid mutations by detecting the presence of heteroduplexes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013668A1 (fr) * 1989-05-05 1990-11-15 Lifecodes Corporation Methode pour l'analyse genetique d'un echantillon d'acide nucleique
EP0405376A2 (fr) * 1989-06-24 1991-01-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Caractérisation de rhinovirus humains
WO1991000925A1 (fr) * 1989-07-13 1991-01-24 Massachusetts Institute Of Technology Determination d'un spectre mutationnel
EP0443748A2 (fr) * 1990-02-06 1991-08-28 National University Of Singapore Caractérisation de type d'antigène de leucocytes humains
WO1992014844A1 (fr) * 1991-02-25 1992-09-03 California Institute Of Biological Research Procede d'amplification enzymatique du genome amorce par une sequence consensuelle permettant de prendre l'empreinte de genomes
WO1993008297A1 (fr) * 1991-10-23 1993-04-29 Baylor College Of Medicine Determination d'empreintes relatives a des souches bacteriennes par amplification repetitive de sequences d'adn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013668A1 (fr) * 1989-05-05 1990-11-15 Lifecodes Corporation Methode pour l'analyse genetique d'un echantillon d'acide nucleique
EP0405376A2 (fr) * 1989-06-24 1991-01-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Caractérisation de rhinovirus humains
WO1991000925A1 (fr) * 1989-07-13 1991-01-24 Massachusetts Institute Of Technology Determination d'un spectre mutationnel
EP0443748A2 (fr) * 1990-02-06 1991-08-28 National University Of Singapore Caractérisation de type d'antigène de leucocytes humains
WO1992014844A1 (fr) * 1991-02-25 1992-09-03 California Institute Of Biological Research Procede d'amplification enzymatique du genome amorce par une sequence consensuelle permettant de prendre l'empreinte de genomes
WO1993008297A1 (fr) * 1991-10-23 1993-04-29 Baylor College Of Medicine Determination d'empreintes relatives a des souches bacteriennes par amplification repetitive de sequences d'adn

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAI, S-P. ET AL: "a rapid and simple electrophoretic method for the detection of mutations involving small insertion or deletion: application to beta thalassemia", HUMAN GENETICS, vol. 87, 1991, BERLIN DE., pages 728 - 730 *
COTTON, R. ET AL: "detection of mutations in DNA", CURRENT OPINIONS IN BIOTECHNOLOGY, vol. 3, January 1992 (1992-01-01), GB., pages 24 - 30 *
COTTON, R.: "current methods of mutation detection", MUTATION RESEARCH, vol. 285, 1993, AMSTERDAM, NL., pages 125 - 144 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020070A1 (fr) * 1995-11-29 1997-06-05 The Anthony Nolan Bone Marrow Trust Procedes pour separer et/ou identifier des molecules d'adn
US6994958B2 (en) 1995-11-29 2006-02-07 Anthony Nolan Bone Marrow Trust Methods for separating and/or identifying DNA molecules
WO2000024935A3 (fr) * 1998-10-26 2000-07-13 Univ Yale Procede fonde sur les differences de frequence d'alleles destine au clonage de phenotypes
ES2190877A1 (es) * 2001-06-26 2003-08-16 Univ Santiago Compostela Metodo gedap (genotyping based on diagnostic amplification products) para detectar y/o prevenir errores de genotipado a partir de los productos de amplificacion de un locus polimorfico.
WO2003001176A3 (fr) * 2001-06-26 2004-03-04 Univ Santiago Compostela Methode de genotypage base sur des produits d'amplification de diagnostic (gedap) servant a la detection et/ou la prevention d'erreurs de genotypage a partir des produits d'amplification d'un locus polymorphique
ES2190877B2 (es) * 2001-06-26 2004-05-16 Universidade De Santiago De Compostela Metodo gedap (genotyping based on diagnostic amplification products) para detectar y/o prevenir errores de genotipado a partir de los productos de amplificacion de un locus polimorfico.
US7402382B2 (en) 2001-06-26 2008-07-22 Universidade De Santiago De Compostela GEDAP method (genotyping based on diagnostic amplification products) for detecting and/or preventing genotyping errors from amplification products of a polymorphic focus
US7935480B2 (en) 2004-12-23 2011-05-03 Health Protection Agency Detection of nucleic acid mutations by detecting the presence of heteroduplexes
GB2435326A (en) * 2006-02-15 2007-08-22 Cell Analysis Ltd Heteroduplex analysis of non-human analytes

Similar Documents

Publication Publication Date Title
Delwart et al. Genetic subtyping of human immunodeficiency virus using a heteroduplex mobility assay.
Loparev et al. Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping
Schochetman et al. Polymerase chain reaction
Yapar et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse transcriptase-PCR
JP2574640B2 (ja) 増幅及びハイブリダイゼーションによるウイルスの検出キット
Pieniazek et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction
Gadkari et al. Transmission of genetically diverse strains of HIV-I in Pune, India
EP0566670A1 (fr) Detection de sequences d'acide nucleique par la formation d'une triple helice de l'adn
Menu et al. HIV type 1 Thai subtype E is predominant in South Vietnam
BACHMANN et al. Rapid genetic characterization of HIV type 1 strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay
Barlow et al. Viral genome characterisation by the heteroduplex mobility and heteroduplex tracking assays
US20070275372A1 (en) Methods and reagents for molecular detection of HIV-1 groups M, N and O
Zaki et al. Genotyping of Entamoeba species in South Africa: diversity, stability, and transmission patterns within families
KR100388548B1 (ko) 알이피 13 이 12 반복서열의 피시알 증폭을 이용한결핵균의 검출방법
UPCROFT et al. Two distinct varieties of Giardia in a mixed infection from a single human patient
Mamadou et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa
WO1995001453A1 (fr) Essai de mobilite des heteroduplex pour l'analyse de la diversite de sequences d'acide nucleique
Novitsky et al. Heteroduplex mobility assay for subtyping HIV-1: improved methodology and comparison with phylogenetic analysis of sequence data
Yeo et al. Rapid detection of codon 460 mutations in the UL97 gene of ganciclovir-resistant cytomegalovirus clinical isolates by real-time PCR using molecular beacons
McCutchan et al. Genetic comparison of human immunodeficiency virus (HIV-1) isolates by polymerase chain reaction
Schindele et al. Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing
Asgharzadeh et al. Current trends in molecular epidemiology studies of Mycobacterium tuberculosis
Thiele The technique of polymerase chain reaction—a new diagnostic tool in microbiology and other scientific fields
WO1993023573A1 (fr) Quantification de l'arn viral par amplification competitive de chaine par polymerase
Donovan et al. Comparison of non-radioactive DNA hybridization probes to detect human immunodeficiency virus nucleic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载